GHK-Cu attracts immune cells to sites of damage, stimulates new blood vessel formation (angiogenesis), and promotes the synthesis of decorin a proteoglycan involved in orderly collagen fiber assembly
This builds confidence and muscle memory for the process
Research in mammalian models demonstrates plasma GHK-Cu concentrations of approximately 200 ng/mL in young organisms, with these levels declining dramatically with age to around 80 ng/mL in aged specimens
High cell density cultivation of Escherichia coli at controlled specific growth rate
Internal Supplements A few people try taking GHK-Cu as a pill or powder, hoping for benefits beyond skincare
New England Journal of Medicine: Retatrutide Phase 2 trial results - The landmark study establishing retatrutide efficacy and safety across multiple dose groups New England Journal of Medicine: STEP 1 semaglutide trial results - The pivotal trial demonstrating semaglutide 2.4 mg weight loss efficacy ClinicalTrials.gov: Retatrutide TRIUMPH program - Current status and details of all ongoing Phase 3 retatrutide trials FDA prescribing information for Wegovy (semaglutide 2.4 mg) - Complete approved labeling including dosing, safety, and clinical data New England Journal of Medicine: SELECT cardiovascular outcomes trial - The trial demonstrating semaglutide 20% reduction in major cardiovascular events These primary sources should be the foundation for any serious evaluation of either compound
